Trial Profile

A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Adenocarcinoma; Endometrial cancer; Leiomyosarcoma; Sarcoma; Uterine cancer
Focus Therapeutic Use
Acronyms HGUS Study

06 Apr 2024 This study has been completed in Belgium and Netherland, accrding to ClinicalTrials.gov: US National Institutes of Health record.
05 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 May 2025.
25 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com